TOP STORIES

• BUSINESS Sakigake: Now and Future (3) - Astellas’s FLT3 Inhibitor for AML Receives Designation, but Other Companies Trailing
  February 19, 2016

• REGULATORY Next Invitation for Sakigake Pathway Might Not Happen Until FY2017, Designations Likely to Decrease: Official
  February 18, 2016

• TRENDS Multiple Authorized Generics Get Approval towards June Listing as Pharmas See Opportunities
  February 17, 2016

• REGULATORY 22 Firms Win Approvals for Zyprexa Generics for June Listing; Kipres AGs Also OK’ed
  February 16, 2016

• TRENDS Japan Drug Makers Foresee 6% Sales Growth in FY2015: Jiho Tally
  February 15, 2016

• REGULATORY Chuikyo Submits Recommendation for FY2016 Reimbursement Policy Reform, New Generic Incentive for Clinics Already Questioned
  February 12, 2016

• BUSINESS Sakigake: Now and Future (2) - Shionogi Aims to Submit Application for Novel Flu Drug as Early as FY2017
  February 12, 2016

• BUSINESS Japan Sales of “Huge Seller” Quartet Each Break 110 Billion Yen in 2015: IMS
  February 10, 2016

• BUSINESS Anticancer Peptide-Drug Conjugates Could Overcome Problems with ADCs: PeptiDream
  February 9, 2016

• REGULATORY Japan, EU to Expand GMP MRA to Cover Europe; Types of Products Covered Might also Be Expanded
  February 8, 2016

• BUSINESS Ayumi Poised to In-License Several RA Biosimilars, Eyes 50 Billion Yen Sales by 2020
  February 5, 2016

• BUSINESS Sakigake: Now and Future (1) - Topical Sirolimus on Track for Application in 2018 for 1st-in-World Indication
  February 4, 2016

• BUSINESS Eisai’s Next Mid-Term Biz Plan Will Show New Twist to Generic Operations: Exec
  February 3, 2016

• BUSINESS Retooling Generic Business - 3: Eisai “Carefully Considering” Future Course; “Not a Core Field,” Mitsubishi Tanabe Says
  February 2, 2016

• BUSINESS Retooling Generic Business - 2: Mochida Seeks to Expand Alliances for Biosimilar Candidates
  February 1, 2016

• BUSINESS Retooling Generic Business - 1: Daiichi Sankyo Espha Shifting Its Focus to AGs
  January 29, 2016

• REGULATORY Suspended-but-Shipped Drugs Should Face 20% Price Cut, Chuikyo Member Says amid Kaketsuken Fuss
  January 28, 2016

• TRENDS 17,800 Hep C Patients Prescribed Sovaldi in 6 Months; Clinical Benefits Out of Consideration in New Re-Pricing Rule
  January 27, 2016

• TRENDS Global Pharmas Mull Excluding Japan from In-Licensing Deals on Annual Revision Fears, Softer Yen
  January 26, 2016

• REGULATORY Gilead’s 2 Hep C Drugs Likely to Face Some 30% Price Cut under “Huge Seller” Re-Pricing: Jiho Estimate
  January 25, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 153
• 154
• 155
• 156
• 157
• 158
• 159
• 160
• 161
• …
• Next ›
• 最終 »